Incidence and risk factors for invasive fungal infections in patients initiating TNF-alpha inhibitors for inflammatory bowel disease and rheumatoid arthritis.

Authors :: Hennessee I
Benedict K
Bahr NC
Lipner SR
Gold JAW
Source :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Sep 03. Date of Electronic Publication: 2024 Sep 03.
Publication Year :: 2024
Publisher :: Ahead of Print
Abstract: In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an IFI within one year of initiating TNF-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.<br /> (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.)

Language :: English
ISSN :: 1537-6591
Database :: MEDLINE
Journal :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publication Type :: Academic Journal
Accession number :: 39223720
Full Text :: https://doi.org/10.1093/cid/ciae444

Full Text Access

Tools